Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Avibactam is a β-lactamase inhibitor that is in clinical development, combined with β-lactam partners, for the treatment of bacterial infections comprising Gram-negative organisms. Avibactam is a structural class of inhibitor that does not contain a β-lactam core but maintains the capacity to covalently acylate its β-lactamase targets. Using the TEM-1 enzyme, we characterized avibactam inhibition by measuring the on-rate for acylation and the off-rate for deacylation. The deacylation off-rate was 0.045 min −1 , which allowed investigation of the deacylation route from TEM-1. Using NMR and MS, we showed that deacylation proceeds through regeneration of intact avibactam and not hydrolysis. Other than TEM-1, four additional clinically relevant β-lactamases were shown to release intact avibactam after being acylated. We showed that avibactam is a covalent, slowly reversible inhibitor, which is a unique mechanism of inhibition among β-lactamase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzyme structure and mechanism
Elmore, D. T. (1978) · Endeavour · doi:10.1016/0160-9327(78)90081-9 · Cited by 2,710
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367 · cited 1×
“Presently, over 1,000 β-lactamases have been documented comprising several structural classes and a wide range of substrate promiscuities and catalytic efficiencies (3, 4).”
BackgroundIrreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090 · cited 2×
“long residence times, indicating stability to hydrolytic deacylation (27, 29).”
BackgroundAntibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
Arias, C. A., & Murray, B. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0804651 · Cited by 1,027
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 913
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Copeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398 · Cited by 678
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Bush, K., & Fisher, J. F. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102911 · Cited by 419
Nordmann, P., Poirel, L., Toleman, M. A., & Walsh, T. R. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq520 · Cited by 294
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes
Bush, K., Macalintal, C., Rasmussen, B. A., Lee, V. J., & Yang, Y. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.851 · Cited by 274
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, K. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.026 · Cited by 241
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity
Ahn, K., Johnson, D. S., Fitzgerald, L. R., Liimatta, M., Arendse, A., Stevenson, T., Lund, E. T., Nugent, R. A., Nomanbhoy, T. K., Alexander, J. P., et al. (2007) · Biochemistry · doi:10.1021/bi701378g · Cited by 216
Copeland, R. A. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003677725 · Cited by 209
In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor
Bonnefoy, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh358 · Cited by 185
Current Challenges in Antimicrobial Chemotherapy: Focus on β-Lactamase Inhibition
Bebrone, C., Lassaux, P., Vercheval, L., Sohier, J.-S., Jehaes, A., Sauvage, E., & Galleni, M. (2010) · Drugs · doi:10.2165/11318430-000000000-00000 · Cited by 159
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
Christensen, H., Martin, M. T., & Waley, S. G. (1990) · PubMed · Cited by 141
Copeland, R. A., Basavapathruni, A., Moyer, M. P., & Scott, M. P. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.05.029 · Cited by 119
Brown, R. P. A., Aplin, R. T., & Schofield, C. J. (1996) · Biochemistry · doi:10.1021/bi961044g · Cited by 111
Endimiani, A., Hujer, K. M., Hujer, A. M., Pulse, M., Weiss, W. J., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-10 · Cited by 77
Three Decades of the Class A β-Lactamase Acyl-Enzyme
Fisher, J. F., & Mobashery, S. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309789351967 · Cited by 70
Charnas, R. L., & Knowles, J. R. (1981) · Biochemistry · doi:10.1021/bi00513a005 · Cited by 69
Fieulaine, S., Boularot, A., Artaud, I., Desmadril, M., Dardel, F., Meinnel, T., & Giglione, C. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001066 · Cited by 51
Mechanism of Inhibition of the Class A β-Lactamases PC1 and TEM-1 by Tazobactam
Yang, Y., Janota, K., Tabei, K., Huang, N., Siegel, M. M., Lin, Y., Rasmussen, B. A., & Shlaes, D. M. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61429-8 · Cited by 50
Yang, Y., Janota, K., Tabei, K., Huang, N., Siegel, M. M., Lin, Y., Rasmussen, B. A., & Shlaes, D. M. (2000) · PubMed · doi:10.1074/jbc.m002369200 · Cited by 43
Tabei, K., Feng, X., Venkatesan, A. M., Abé, T., Ushirogochi, H., Mansour, T. S., & Siegel, M. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049903j · Cited by 29
Matagne, A., Ghuysen, M. F., & Frère, J. (1993) · Biochemical Journal · doi:10.1042/bj2950705 · Cited by 23
Reversible acylation of elastase by γ-lactam analogues of β-lactam inhibitors
Westwood, N. J., Claridge, T. D. W., Edwards, P. N., et al. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10123-8 · Cited by 14
Inhibition of the RTEM-1 β-lactamase by boronic acids
Martin, R., Gold, M. H., & Jones, J. B. (1994) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)80336-x · Cited by 12
Cited by
β-Lactams and β-Lactamase Inhibitors: An Overview
Bush, K., & Bradford, P. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025247 · Cited by 1,412
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
β-lactam antibiotics: An overview from a medicinal chemistry perspective
Lima, L. M., Silva, B. N. M. D., Barbosa, G., & Barreiro, E. J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112829 · Cited by 642
Combination approaches to combat multidrug-resistant bacteria
Worthington, R. J., & Melander, C. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.006 · Cited by 625
van Duin, D., & Bonomo, R. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw243 · Cited by 549
Metadata
- Authors
- Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-07-02
- Volume
- 109
- Issue
- 29
- Pages
- 11663-11668
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2068735589
- Cited by
- 545
- References
- 32
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.